Multimorbidity is common and associated with adverse outcomes in heart failure (HF). However, its prognostic value across frailty states is uncertain, particularly whether comorbidities continue to stratify risk once frailty develops.
To evaluate whether frailty modifies the association of multimorbidity i...
V. Copeland, B. Fishman, S. Elimelech et al.· European Heart Journal· 0 citations
Frailty is a multidimensional syndrome of reduced physiologic reserve associated with adverse outcomes in heart failure (HF). Whether its underlying drivers and prognostic significance differ by age remains poorly understood.
To assess age-specific correlations of frailty, predictors of incident frailty, a...
V. Copeland, B. Fishman, S. Elimelech et al.· European Heart Journal· 0 citations
Cardiovascular-kidney-metabolic (CKM) syndrome is a systemic disorder defined by the overlapping burden of heart failure (HF), chronic kidney disease (CKD), diabetes, and obesity. Although sex differences in cardiovascular disease are increasingly recognized, sex-specific patterns of mortality and renal progressi...
D. Hochstein, R. Loutati, V. Copeland et al.· European Heart Journal· 0 citations
Left ventricular hypertrophy is a hallmark of adverse remodeling in heart failure (HF), yet commonly used echocardiographic measures provide limited insight into sex-specific risk. Interventricular septal (IVS) thickness is routinely measured, but its independent prognostic value and potential sex-related differe...
A. Kaplan, V. Copeland, R. Loutati et al.· European Heart Journal· 0 citations
BACKGROUND
Hypertension (HTN) is a common comorbidity in patients with heart failure with reduced ejection fraction (HFrEF), yet its prognostic significance remains complex.
OBJECTIVE
To evaluate the association between HTN and all-cause mortality in patients with HFrEF, stratified by ischemic and nonischemic etiolog...
Daniel Zango, V. Copeland, Y. Wasserstrum et al.· Journal of Hypertension· 0 citations
In patients with late-stage metabolic syndrome, CKD identifies a high-risk subgroup with a graded increase in mortality and dialysis risk compared with eGFR ≥60, and the heightened dialysis risk remained pronounced after accounting for competing death.
D. Hochstein, R. Loutati, V. Copeland et al.· European Heart Journal· 0 citations
In patients with heart failure and advanced chronic kidney disease, CCBs use was associated with improved survival, supporting their potential role as a safe adjunctive therapy for blood pressure control in this high-risk population.
V. Copeland, A. Milwidsky, S. Elimeleh et al.· American Journal of Medicine· 0 citations
Frailty fundamentally attenuates risk in HF, while multimorbidity stratifies prognosis only when physiological reserve is preserved, while multimorbidity stratifies prognosis only when physiological reserve is preserved.
V. Copeland, Boris Fishman, S. Elimeleh et al.· Mayo Clinic proceedings· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.